# AMP-518 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/amp-518

> AMP-518, sponsored by AIM ImmunoTech Inc. (AIM): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | AMP-518 |
| Codes | AMP-518 |
| Sponsor | AIM ImmunoTech Inc. (AIM) https://sec-api.dev/companies/aim/catalysts |
| Indications | post-covid conditions |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jul 2023: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: post-COVID conditions.
- First seen 2024-11-14, last confirmed 2026-11-12.
- SEC Form 10-Q (accession 0001493152-26-051439): "July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions ("AMP-518")." https://www.sec.gov/Archives/edgar/data/946644/000149315226051439/form10-q.htm
- SEC Form 10-Q (accession 0001493152-26-051439): "July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen as a potential therapeutic for people with post-COVID conditions ("AMP-518")." https://www.sec.gov/Archives/edgar/data/946644/000149315226051439/form10-q.htm
- SEC Form 10-Q (accession 0001493152-26-036609): "July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions ("AMP-518")." https://www.sec.gov/Archives/edgar/data/946644/000149315226036609/form10-q.htm
- SEC Form 10-Q (accession 0001493152-26-036609): "July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen as a potential therapeutic for people with post-COVID conditions ("AMP-518")." https://www.sec.gov/Archives/edgar/data/946644/000149315226036609/form10-q.htm
- SEC registration statement (S-1) (accession 0001493152-26-029193): "July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions ("AMP-518")." https://www.sec.gov/Archives/edgar/data/946644/000149315226029193/forms-1.htm
- SEC prospectus (424B) (accession 0001493152-26-028088): "July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions ("AMP-518")." https://www.sec.gov/Archives/edgar/data/946644/000149315226028088/form424b5.htm
- SEC registration statement (S-1) (accession 0001493152-26-027714): "July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions ("AMP-518")." https://www.sec.gov/Archives/edgar/data/946644/000149315226027714/forms-1.htm
- SEC Form 10-Q (accession 0001493152-26-023750): "July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions ("AMP-518")." https://www.sec.gov/Archives/edgar/data/946644/000149315226023750/form10-q.htm
- SEC Form 10-Q (accession 0001493152-26-023750): "July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen as a potential therapeutic for people with post-COVID conditions ("AMP-518")." https://www.sec.gov/Archives/edgar/data/946644/000149315226023750/form10-q.htm
- SEC Form 10-K (accession 0001493152-26-013301): "July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions ("AMP-518")." https://www.sec.gov/Archives/edgar/data/946644/000149315226013301/form10-k.htm
- SEC Form 10-Q (accession 0001493152-25-023894): "July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions ("AMP-518")." https://www.sec.gov/Archives/edgar/data/946644/000149315225023894/form10-q.htm
- SEC Form 10-Q (accession 0001493152-25-011986): "July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions ("AMP-518")." https://www.sec.gov/Archives/edgar/data/946644/000149315225011986/form10-q.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/amp-518.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AMP-518 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/amp-518

```bibtex
@misc{secapidev_pdufa_amp_518_20261116,
  title        = {AMP-518 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/amp-518}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_amp_518_20261116","title":"AMP-518 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/amp-518","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
